Figure 4.

The anti-tumor efficacy of GD2-CAR NK-92 cells in NCG mice bearing TT190326 DIPG cells (low GD2 expression). (A, B) Luciferase-containing engineered TT190326 DIPG cells were implanted into the brainstem of NCG mice. Two weeks later, mice with established orthotopic TT190326 DIPGs were randomly assigned to control, NK-92 cells treated and GD2-CAR NK-92 cells-treated groups, respectively. PBS, 3×10⁶ NK-92 cells, and 3×10⁶ GD2-CAR NK-92 cells were injected into the lateral ventricle of NCG mice weekly for two weeks. Normalized luminescence was analyzed by Living Image software Version 3.0 (Caliper Life Sciences). (C) Kaplan–Meier survival curve plotting. Log-rank test was performed to compare survival between the groups. (D) Release assay of various cytokines in the plasma from NCG mice bearing TT190326 DIPG cells. Mice were treated with PBS, NK-92 cells, and GD2-CAR NK-92 cells, respectively. Three days later, mice were sacrificed to collect plasma and levels of indicated cytokines were measured by a cytokine release array assay. P < 0.05 (∗). NS, No Significance.